Nerigoside suppresses colorectal cancer cell growth and metastatic potential through inhibition of ERK/GSK3β/β-catenin signaling pathway
Authors:
- 1 April 2019
- journal article
- research article
- Published by Elsevier in Phytomedicine
- Vol. 57, 352-363
Abstract
No abstract availableKeywords
Funding Information
- Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research (2016B 030301004)
This publication has 28 references indexed in Scilit:
- Wnt/β-Catenin Signaling and DiseaseCell, 2012
- Wnt/β-catenin Signaling in Oral Tissue Development and DiseaseJournal of Dental Research, 2010
- Wnt/β-Catenin Signaling: Components, Mechanisms, and DiseasesDevelopmental Cell, 2009
- Knockin of mutant PIK3CA activates multiple oncogenic pathwaysProceedings of the National Academy of Sciences, 2009
- Wnt/β-Catenin Signaling in Development and DiseaseCell, 2006
- Detection of Active Fraction of Glycogen Synthase Kinase 3β in Cancer Cells by Nonradioisotopic in vitro Kinase AssayOncology, 2006
- A dual-kinase mechanism for Wnt co-receptor phosphorylation and activationNature, 2005
- Deregulated GSK3β activity in colorectal cancer: Its association with tumor cell survival and proliferationBiochemical and Biophysical Research Communications, 2005
- Axin-mediated CKI phosphorylation of β-catenin at Ser 45: a molecular switch for the Wnt pathwayGenes & Development, 2002
- Frequent Alterations of the β-Catenin Protein in Cancer of the Uterine CervixTumor Biology, 2002